Belite Bio, Inc (BLTE)Healthcare | Biotechnology | San Diego, United States | NasdaqCM
165.45 USD
+7.40
(4.682%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 165.00 -0.45 (-0.450%) ⇩ (April 17, 2026, 4:31 p.m. EDT) Short-term: ★★★☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:08 a.m. EDT
Despite 'Strong Buy' analyst sentiment and technical recovery from lows, BLTE is fundamentally broken with negative earnings, massive negative operating cash flow, and a 210x forward P/E. Recent insider selling and a neutral short-term model forecast suggest the 'build-up' phase of the 52-week range is over, leaving it a high-risk speculative hold rather than a momentum play. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.062101 |
| MSTL | 0.064285 |
| AutoTheta | 0.102132 |
| AutoARIMA | 0.187264 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.56 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.293 |
| Excess Kurtosis | -0.31 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.056 |
| Market Cap | 6,612,260,864 |
| Forward P/E | 210.76 |
| Beta | -1.22 |
| Website | https://www.belitebio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 2.025233 |
| Address1 | 12,750 High Bluff Drive |
| Address2 | Suite 475 |
| All Time High | 200.0 |
| All Time Low | 8.8 |
| Ask | 166.48 |
| Ask Size | 1 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 175,620 |
| Average Daily Volume3 Month | 189,793 |
| Average Volume | 189,793 |
| Average Volume10Days | 175,620 |
| Beta | -1.223 |
| Bid | 163.39 |
| Bid Size | 1 |
| Book Value | 19.585 |
| City | San Diego |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 165.45 |
| Current Ratio | 50.017 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 165.705 |
| Day Low | 158.1 |
| Debt To Equity | 0.056 |
| Display Name | Belite Bio |
| Earnings Call Timestamp End | 1,772,487,000 |
| Earnings Call Timestamp Start | 1,772,487,000 |
| Earnings Timestamp | 1,772,458,200 |
| Earnings Timestamp End | 1,778,589,000 |
| Earnings Timestamp Start | 1,778,589,000 |
| Ebitda | -84,024,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -71.608 |
| Enterprise Value | 6,016,803,328 |
| Eps Current Year | -2.13 |
| Eps Forward | 0.785 |
| Eps Trailing Twelve Months | -2.32 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 171.0077 |
| Fifty Day Average Change | -5.5577087 |
| Fifty Day Average Change Percent | -0.032499757 |
| Fifty Two Week Change Percent | 202.5233 |
| Fifty Two Week High | 200.0 |
| Fifty Two Week High Change | -34.550003 |
| Fifty Two Week High Change Percent | -0.17275001 |
| Fifty Two Week Low | 53.595 |
| Fifty Two Week Low Change | 111.854996 |
| Fifty Two Week Low Change Percent | 2.0870416 |
| Fifty Two Week Range | 53.595 - 200.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,651,239,000,000 |
| Float Shares | 18,517,713 |
| Forward Eps | 0.785 |
| Forward P E | 210.76431 |
| Free Cashflow | -9,765,250 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 41 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.43877 |
| Held Percent Institutions | 0.18521999 |
| Implied Shares Outstanding | 39,965,314 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd. |
| Long Name | Belite Bio, Inc |
| Market | us_market |
| Market Cap | 6,612,260,864 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1776217412 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -77,611,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 6,617,856,345 |
| Number Of Analyst Opinions | 8 |
| Open | 162.0 |
| Operating Cashflow | -36,988,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 858 246 6240 |
| Post Market Change | -0.44999695 |
| Post Market Change Percent | -0.27198365 |
| Post Market Price | 165.0 |
| Post Market Time | 1,776,457,887 |
| Previous Close | 158.05 |
| Price Eps Current Year | -77.67605 |
| Price Hint | 2 |
| Price To Book | 8.447792 |
| Profit Margins | 0.0 |
| Quick Ratio | 49.901 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.25 |
| Region | US |
| Regular Market Change | 7.39999 |
| Regular Market Change Percent | 4.68206 |
| Regular Market Day High | 165.705 |
| Regular Market Day Low | 158.1 |
| Regular Market Day Range | 158.1 - 165.705 |
| Regular Market Open | 162.0 |
| Regular Market Previous Close | 158.05 |
| Regular Market Price | 165.45 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 171,545 |
| Return On Assets | -0.11286 |
| Return On Equity | -0.1694 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 39,965,314 |
| Shares Percent Shares Out | 0.026099999 |
| Shares Short | 1,044,796 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 792,323 |
| Short Name | Belite Bio, Inc |
| Short Percent Of Float | 0.0505 |
| Short Ratio | 5.77 |
| Source Interval | 15 |
| State | CA |
| Symbol | BLTE |
| Target High Price | 266.0 |
| Target Low Price | 185.0 |
| Target Mean Price | 211.5 |
| Target Median Price | 200.5 |
| Total Cash | 492,422,016 |
| Total Cash Per Share | 12.517 |
| Total Debt | 429,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.32 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 120.15275 |
| Two Hundred Day Average Change | 45.29725 |
| Two Hundred Day Average Change Percent | 0.3769972 |
| Type Disp | Equity |
| Volume | 171,545 |
| Website | https://www.belitebio.com |
| Zip | 92,130 |